Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе: https://open.uns.ac.rs/handle/123456789/10109
Pоljе DC-аVrеdnоstЈеzik
dc.contributor.authorMirjana Bećarevićen_US
dc.contributor.authorJelena Seferovićen_US
dc.contributor.authorSvetlana Ignjatovićen_US
dc.contributor.authorSandra Singhen_US
dc.contributor.authorNada Majkić-Singhen_US
dc.date.accessioned2020-03-03T14:37:24Z-
dc.date.available2020-03-03T14:37:24Z-
dc.date.issued2012-07-01-
dc.identifier.issn14528258en_US
dc.identifier.urihttps://open.uns.ac.rs/handle/123456789/10109-
dc.description.abstractThe importance of the association of antiphospholipid antibodies (aPL Abs) with the features of type II diabetes mellitus has not yet been elucidated. The aim of this work was to investigate the association of aPL Abs with adiponectin and non-esterified fatty acids (NEFA) in type II diabetes mellitus patients without micro and/or macrovascular complications, and to analyze the differences between the male and female patients with regard to the abovementioned parameters. Male patients with type II diabetes mellitus showed a positive correlation between NEFA concentrations and anti-oxLDL antibodies (r=0.334, p=0.019). A weak, but statistically significant correlation between adiponectin concentrations and the IgM isotype of anti-annexin A5 antibodies was found in type II diabetes mellitus patients (r=0.285, p=0.011). The presence of a positive correlation between NEFA and anti-oxLDL antibodies might be useful in the detection of patients with premature atherosclerosis in type II diabetes mellitus patients without any micro and/or macrovascular complications among type II diabetes mellitus patients.en_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Medical Biochemistryen_US
dc.subjectantiphospholipid antibodiesen_US
dc.subjectadiponectinen_US
dc.subjectdiabetes mellitus type IIen_US
dc.subjectantifosfolipidna antitelaen_US
dc.subjectadiponektinen_US
dc.titleAdiponectin, non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitusen_US
dc.typeArticleen_US
dc.identifier.doi10.2478/v10011-012-0009-y-
dc.identifier.scopus2-s2.0-84861860611-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/84861860611-
dc.description.versionPublisheden_US
dc.relation.lastpage204en_US
dc.relation.firstpage199en_US
dc.relation.issue3en_US
dc.relation.volume31en_US
item.fulltextNo Fulltext-
item.grantfulltextnone-
crisitem.author.deptKatedra za farmaciju-
crisitem.author.orcid0000-0003-2114-8621-
crisitem.author.parentorgMedicinski fakultet-
Nаlаzi sе u kоlеkciјаmа:MDF Publikacije/Publications
Prikаzаti јеdnоstаvаn zаpis stаvki

SCOPUSTM   
Nаvоđеnjа

6
prоvеrеnо 26.08.2023.

Prеglеd/i stаnicа

63
Prоtеklа nеdеljа
14
Prоtеkli mеsеc
6
prоvеrеnо 10.05.2024.

Google ScholarTM

Prоvеritе

Аlt mеtrikа


Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.